- Home
- GLRE vs CAPR Comparison
GLRE vs CAPR Comparison
Compare GLRE & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLRE
- CAPR
- Stock Information
- Founded
- GLRE 2004
- CAPR 2005
- Country
- GLRE Cayman Islands
- CAPR United States
- Employees
- GLRE N/A
- CAPR N/A
- Industry
- GLRE Property-Casualty Insurers
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GLRE Finance
- CAPR Health Care
- Exchange
- GLRE Nasdaq
- CAPR Nasdaq
- Market Cap
- GLRE 486.3M
- CAPR 578.4M
- IPO Year
- GLRE 2007
- CAPR N/A
- Fundamental
- Price
- GLRE $14.12
- CAPR $13.70
- Analyst Decision
- GLRE
- CAPR Strong Buy
- Analyst Count
- GLRE 0
- CAPR 7
- Target Price
- GLRE N/A
- CAPR $39.29
- AVG Volume (30 Days)
- GLRE 83.9K
- CAPR 1.1M
- Earning Date
- GLRE 03-04-2025
- CAPR 02-27-2025
- Dividend Yield
- GLRE N/A
- CAPR N/A
- EPS Growth
- GLRE N/A
- CAPR N/A
- EPS
- GLRE 2.53
- CAPR N/A
- Revenue
- GLRE $702,254,000.00
- CAPR $23,228,045.00
- Revenue This Year
- GLRE N/A
- CAPR N/A
- Revenue Next Year
- GLRE N/A
- CAPR $74.85
- P/E Ratio
- GLRE $5.58
- CAPR N/A
- Revenue Growth
- GLRE 8.96
- CAPR 65.33
- 52 Week Low
- GLRE $11.01
- CAPR $3.52
- 52 Week High
- GLRE $15.82
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- GLRE 51.61
- CAPR 45.79
- Support Level
- GLRE $13.42
- CAPR $12.31
- Resistance Level
- GLRE $14.31
- CAPR $16.17
- Average True Range (ATR)
- GLRE 0.29
- CAPR 0.83
- MACD
- GLRE 0.06
- CAPR 0.07
- Stochastic Oscillator
- GLRE 78.65
- CAPR 36.01
About GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed, and income from investments.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.